Table 4.
Immunotherapy Combined with Targeted Therapy for HCC
Drugs | Phase | Participants | ClinicalTrials.gov | Start Date | Status | Reference |
---|---|---|---|---|---|---|
Camrelizumab + Apatinib | II | 20 | NCT04297202 | December 1, 2019 | Recruiting | [143] |
Cabozantinib + Atezolizumab | III | 740 | NCT03755791 | June 10, 2018 | Active, not recruiting | [144] |
Regorafenib + Pembrolizumab | I | 58 | NCT03347292 | June 18, 2018 | Completed | |
Regorafenib + Avelumab | I/II | 482 | NCT03475953 | May 4, 2018 | Recruiting | [145] |
Cabozantinib + Nivolumab | I | 15 | NCT03299946 | May 14, 2018 | Completed | [146] |
Cabozantinib + Durvalumab | I/II | 117 | NCT03539822 | October 22, 2018 | Active, not recruiting | |
Ramucirumab + Durvalumab | I | 85 | NCT02572687 | February 19, 2016 | Completed | |
Bevacizumab + Erlotinib | II | 45 | NCT01180959 | April 14, 2011 | Completed | [147] |
Sorafenib + Nivolumab | II | 24 | NCT03439891 | April 16, 2018 | Active, not recruiting | |
Tivozanib + Durvalumab | I/II | 42 | NCT03970616 | September 30, 2019 | Terminated | [148] |
Tislelizumab + Lenvatinib | II | 30 | NCT04834986 | April 30, 2021 | Not yet recruiting | |
Camrelizumab + Apatinib | II | 40 | NCT04826406 | February 3, 2021 | Recruiting | |
Atezolizumab + Bevacizumab | III | 668 | NCT04102098 | December 31, 2019 | Active, not recruiting | [149] |
Durvalumab + Tremelimumab | III | 1324 | NCT03298451 | October 11,2017 | Active, not recruiting | [150] |
Donafenib + Sintilimab | II | 30 | NCT05162352 | December 4, 2021 | Recruiting | |
Camrelizumab + Apatinib | III | 674 | NCT04639180 | April 1, 2021 | Not recruiting |